The Top 5 Biosimilars Articles for the Week of September 24

September 28, 2018

The Center for Biosimilars® recaps the top news for the week of September 24, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 24.

Number 5: The latest review seeking to reassure clinicians about the safety of switching their patients to biosimilars focuses on rheumatology indications.

Number 4: The National Health Service’s Specialist Pharmacy Service released resources for clinicians to use with patients in the discussions around switching from the reference Humira to a biosimilar.

Number 3: A United Kingdom court has ruled in favor of the National Health Service, allowing the health service to treat patients with age-related macular degeneration with bevacizumab.

Number 2: The Congressional Budget Office announced its cost estimate of implementing the CREATES Act, noting that it expects the bill’s provisions would allow generics and biosimilars to enter the market earlier, on average, than they would under current law.

Number 1: The European Union has authorized its first 2 pegfilgrastim biosimilars this week to be sold as Udenyca and Pelgraz, respectively.

Finally, last week, our e-newsletter asked what’s the most important next step for the FDA to take to encourage increased biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.